Your browser doesn't support javascript.
loading
Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management.
De Man, Kathia; Piron, Sarah; Van Laeken, Nick; Delrue, Louke; Fonteyne, Valérie; Lumen, Nicolaas; Van den Broeck, Bliede; Kersemans, Ken; Ost, Piet; Schelfhout, Vanessa.
Afiliação
  • De Man K; Department of Medical Imaging, Nuclear Medicine, Ghent University Hospital, Corneel Heymanslaan 10, Ghent, Belgium. kathia.deman@uzgent.be.
  • Piron S; Laboratory of Radiopharmacy, Ghent University, Ghent, Belgium.
  • Van Laeken N; Department of Medical Imaging, Nuclear Medicine, Ghent University Hospital, Corneel Heymanslaan 10, Ghent, Belgium.
  • Delrue L; Department of Medical Imaging, Radiology, Ghent University Hospital, Ghent, Belgium.
  • Fonteyne V; Department of Radiation-Oncology, Ghent University Hospital, Ghent, Belgium.
  • Lumen N; Department of Urology, Ghent University Hospital, Ghent, Belgium.
  • Van den Broeck B; Department of Medical Imaging, Nuclear Medicine, Ghent University Hospital, Corneel Heymanslaan 10, Ghent, Belgium.
  • Kersemans K; Department of Medical Imaging, Nuclear Medicine, Ghent University Hospital, Corneel Heymanslaan 10, Ghent, Belgium.
  • Ost P; Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
  • Schelfhout V; Department of Radiation-Oncology, Iridium Network, Wilrijk, Belgium.
Mol Imaging Biol ; 24(5): 750-758, 2022 10.
Article em En | MEDLINE | ID: mdl-35411446
PURPOSE: In this study, we evaluated the impact of 18F-PSMA-11 PET/CT on the patient management plan in patients with primary or recurrent disease. Furthermore, a correlation between PET findings and other modalities was performed. PROCEDURES: In this prospective observational study, 60 prostate cancer patients (9 primary staging, 51 biochemical recurrence) were imaged with 18F-PSMA-11 PET/CT. Pre- and post-scan questionnaires were completed by the treating physician to observe changes in therapy intent. Follow-up data (histological confirmation, MRI imaging, and PSA values after radiotherapy without implementation of systemic therapy) was correlated with the 18F-PSMA-11 findings. RESULTS: The patient-based detection rate was 82% and a management change was seen in 52% of the cases. The heterogeneous characteristics of the included patients resulted in a widely varying treatment change, mostly originating from an increase of disease extent on 18F-PSMA-11 PET/CT. CONCLUSION: 18F-PSMA-11 PET/CT showed to be a highly promising method for the detection of prostate cancer lesions.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada Idioma: En Ano de publicação: 2022 Tipo de documento: Article